chronic lymphocytic leukemia cll common form adult leukemia neoplastic cells patients disease accumulate result defective programmed cell death response standard chemotherapeutic agents drug resistance routinely develops increased understanding molecular basis relative chemoresistance heterogeneity specific tumor cell subpopulations facilitate development innovative therapeutic strategies new agents potentially circumvent recognized mechanisms resistance introduced clinic proposal focus identifying specific patient populations ultimately targeted novel therapeutic agents based upon molecular characterization leukemic cells predict either response failure standard chemotherapeutic agents furthermore use alternatives vitro predictive assays also facilitate recognition likely either response transient response standard agents thus enable patients avoid unnecessary toxicity finally availability powerful technological advances cdna microarrays used examine differential expression genes relevant drug induced apoptosis leukemic cells observations correlated known chromosomal aberrations specified levels protein expression within malignant cell substantial increment understanding drug sensitivity resistance potentially result genomic research